On Air Now

Upcoming Shows

Program Schedule »

Tune in to Listen

650 AM Hibbing, Minnesota

Weather

Current Conditions(Hibbing,MN 55746)

More Weather »
62° Feels Like: 62°
Wind: WSW 0 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Today

Scattered Thunderstorms 77°

Tonight

Partly Cloudy 55°

Tomorrow

Sunny 84°

Alerts

FDA grants priority review status to Gilead's hepatitis C drug

(Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.

The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.

The FDA set a review date of December 8 for the drug, Gilead said.

Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue.

Drugmakers AbbVie and Bristol-Myers Squibb are also developing such treatments but they require patient to take more pills each day than Gilead's treatment.

(Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian)

Comments